Showing posts with label QCOR. Show all posts
Showing posts with label QCOR. Show all posts

Monday, July 11, 2011

ICResearch Q2 2011 Performance (BKS, PHH, QCOR, VVUS, RCL, LL, ODP, EK, BBY, WFC, CREE, AIG, LOGI, PHG, WWE, NYB, LCC, CCL)

InvestingConsultantResearch.com today announced results for the quarterly performance of it's recommendations made for the second quarter of 2011. Here is how those recommendations for Q2 2011 performed since they were issued, ordered by return for the cautious investor if they had been held until market closes at the end of the second quarter of 2011 or when the bid price reached the level provided in the exit strategy.

To be fairly representative of the potential performance, the return presents what an investor would have earned opening the position at the prevailing price when the report was issued and closing it when the bid price of the stock reached the suggested exit point. If the stock did not reach any of the exit levels, the closing price at the end of the quarter is considered to be the selling price.


For the cautious investor:
BKS: + 120%
QCOR: + 85%
VVUS: + 43%
WDC: + 40%
DYAX: + 32%
CRU: + 32%
ARNA: + 30%
IGOI: + 30%
RCL: + 29%
DV: + 29%
EXF: + 27%
EXFO: + 25%
FCN: + 22%
SYNA: + 21%
AXL: + 18%
FBC: + 18%
VCI: + 18%
SANM: + 18%
MDAS: + 17%
LCC: + 17%
SWM: + 15%
FLML: + 15%
RDN: + 13%
LL: + 13%
ORN: + 12%
ODP: + 12%
EK: + 11%
MTOR: + 11%
BORN: + 10%
BBY: + 10%
JACK: + 10%
ENG: + 7%
LOJN: + 7%
PHH: + 7%
FEED: + 5%
XRTX: + 5%
SCCO: + 5%
RJET: + 4%
BPL: + 4%
WFSL: + 4%
NYB: + 4%
WFC: + 2%
FRO: + 1%
HBOS: - 1%
CREE: - 2%
PHG: - 2%
CCL: - 2%
LOGI: - 4%
LPS: - 6%
RECN: - 8%
AIG: - 9%
WWE: - 11%
SATC: - 14%
ANAD: - 20%
HSOL: - 25%
MTSN: - 26%

Average Return: + 13%


Once again, the return presents what an investor would have earned opening the position at the prevailing price of the option contract when the report was issued and closing it when the bid price of the contract reached the suggested exit point. If the stock did not reach any of the exit levels, the closing bid price at the end of the quarter is considered to be the selling price of the option contract.


For the risk taking trader:

Average Return: + 66%


Most of InvestingConsultantResearch.com's picks returned modest performance and some even suffered losses, but the losses were offset by the provided exit strategy. Subscribe to our our site to stay informed for forthcoming recommendations for Q3 and Q4 2011 or follow us on Twitter.

Monday, March 14, 2011

Questcor Pharmaceuticals Inc (NASDAQ: QCOR) Q2 2011 Price Target

Recent price: 13.45$
P/E Ratio: 24.90
3 Months Target Price: 14.77$

Company Description
According to Reuters, Questcor Pharmaceuticals Inc is a pharmaceutical company focused on diseases and disorders. Questcor’s primary drug is H.P. Acthar Gel (repository corticotropin injection), an injectable drug that is approved by the United States Food and Drug Administration (FDA) for the treatment of a variety of diseases and disorders. Acthar is also used in treating patients with infantile spasms (IS), a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder, but is not approved for the treatment of either disorder. Acthar is approved to induce a diuresis or a remission of proteinuria in the nephrotic syndrome (NS) without uremia of the idiopathic type or that due to lupus erythamatosus. The Company also markets Doral (quazepam), which is indicated for the treatment of insomnia. As of December 31, 2009, Acthar is approved in the United States for the treatment of multiple sclerosis (MS) exacerbations, nephrotic syndrome and many other conditions.


Confidence Margins
Strong resistance $16.67 (+24%)
Light resistance $14.77 (+10%)
Light support $12.16 (-10%)
Strong support $9.33 (-31%)

Recommendation
Shares of Questcor Pharmaceuticals fell during the month of February after an article published in the Barron's over the weekend, raised concerns about sales of the company's main drug Acthar. Even if this information proves to have grounds in the long term, shares of the company are currently trading at interesting multiples and offer a good entry point in the stock.

Entry strategy
For the cautious investor:
Buy the stock for 14$ or less.

For the risk-taking trader:
The July 2011 14$ out-of-the-money call option contract seems to be the right position to take, they can be acquired for about 190$ per contract.

Exit Strategy
For the cautious investor:
Sell when the stock reaches 14.75$, or keep it until 16$ if you are more bullish in your own analysis. It is highly recommended to keep the position on check if it goes sour.

For the risk-taking trader:
The contracts should be kept until the underlying reaches around 14.75$. This should provide a satisfactory return if the underlying reaches the target price as the contracts will get in the money.